key: cord-0792575-nmlyws4m
authors: Allocca, Mariangela; Guidelli, Giacomo Maria; Borroni, Riccardo G.; Selmi, Carlo; Narcisi, Alessandra; Danese, Silvio; Fiorino, Gionata
title: Clinical course of COVID-19 in 41 patients with immune-mediated inflammatory diseases: experience from Humanitas Center, Milan
date: 2020-07-03
journal: Pharmacol Res
DOI: 10.1016/j.phrs.2020.105061
sha: d4a59b63ac6562d0cc1ed9da822f599f7e841788
doc_id: 792575
cord_uid: nmlyws4m

nan

the value 0 if they don't). All the parameters described in Table 2 were employed as explanatory variables (or independent variables). Univariable analysis was used to identify candidate predictors. Then, a multivariable model was fitted using a "backwards elimination procedure". All variables with p < 0.05

were retained in the model. Multivariable analysis revealed that only coexisting comorbidities were associated with increased risk of hospitalization and oxygen therapy ( Table 2) .

Immunosuppression is expected to weaken the immune system response in patients with COVID-19 infection and concomitant IMID and possibly lead to worse outcomes. However, some studies suggest that active disease, older age and comorbidities may also be associated with COVID-19 negative outcomes, such as pneumonia, hospitalization and death [5] . Our data confirm that the presence of comorbidities, such as hypertension, diabetes, obesity and chronic lung disease, may increase the risk of hospitalization and the need of oxygen supplementation [6] . Despite limitations created by a small sample size, our study suggests using caution especially when administering steroid therapy, wheras biologic therapy seems safe since no association between the use of biologic therapy and a worse pattern of COVID-19 infection was observed.

In conclusion, patients with IMID and on a stable steroid-free remission under immunosuppression are not at increased risk of worse outcomes from COVID-19. Caution should be paid to older patients with comorbidities and concomitant chronic glucocorticoid intake.

J o u r n a l P r e -p r o o f IMID Immuno-Mediated Inflammatory Diseases; Data are presented as medians (interquartile range) or percentages when appropriate; * 8 health workers, 1 police officer; § Metabolic disorders include diabetes, obesity, metabolic syndrome; § § 1 renal carcinoma, 1 prostate cancer.

Prevention of COVID-19 in patients with inflammatory bowel disease in Wuhan, China. The lancet

Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the Nancy and Milan cohorts

The impact of COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biologic therapy: the Northern Italy experience

COVID-19: Immunology and treatment options

Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study

Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: A systematic review and meta-analysis